Skip to main content

Table 4 Antiretroviral concentration in hair by viral suppression status at baseline and 6 -months (N = 77)a

From: A group-based mental health intervention for young people living with HIV in Tanzania: results of a pilot individually randomized group treatment trial

  Baseline 6 -Months
Virologic suppression Virologic failure Virologic suppression Virologic Failure
Nevirapine (N = 13) 48.37 (13.92)
N = 11
19.65 (17.75)
N = 2
51.46 (19.43)
N = 11
30.35 (11.53)
N = 2
Efavirenz (N = 29) 8.53 (6.50)
N = 21b
2.53 (1.58)
N = 7b
8.59 (6.16)
N = 22
3.13 (2.46)
N = 7
Lopinavir (N = 15) 9.56 (5.49)
N = 8
2.57 (4.19)
N = 7
13.85 (8.37)
N = 9
1.30 (1.86)
N = 6
Atazanavir (N = 20) 7.56 (2.96)
N = 13
1.56 (1.69)
N = 7
6.15 (3.08)
N = 15
1.91 (1.85)
N = 5
Standardized hair concentration (N = 77) 0.19 (1.56)
N = 53b
−2.48 (2.28)
N = 23b
0.11 (1.13)
N = 57
−1.52 (1.39)
N = 20
  1. aAll summaries are reported as means (standard deviations)
  2. bOne participant was missing viral load information at baseline
  3. Virologic suppression: HIV RNA < 400 copies/mL; virologic failure: HIV RNA ≥400 copies/mL